NeuBase Therapeutics with ticker code (NBSE) have now 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 18 and 15 and has a mean target at 16.8. With the stocks previous close at 10.46 this now indicates there is a potential upside of 60.6%. The day 50 moving average is 9.48 and the 200 day moving average is 8.47. The company has a market cap of $236m. Company Website: http://www.neubasetherapeutics.com
NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington’s disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.